Altimmune, Inc. · NASDAQ:ALT
Altimmune — BIO Investor Forum 2019
20 slides from Altimmune's conference presentation, Oct 23, 2019
Slide 1: BIO Investor Forum
BIO Investor Forum 23 October 2019 1
Slide 2: Forward-looking Statement Disclosure
Forward-looking Statement Disclosure Safe-Harbor Statement Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for comm
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Diversified pipeline of product candidates that address large market opportunities Near-term value-driving catalysts in multiple therapeutic programs $42M cash on hand to support development programs and sustain operations through catalysts Management team and infrastructure in
Slide 4: Development Pipeline
Development Pipeline Multiple paths to value creation PRODUCT PRECLINICAL PHASE 1 PHASE II PHASE III ALT-801 NASH Advancing into Phase 1 development 2020 LIVER DISEASES HepTcellTM Chronic Hepatitis B Advancing into Phase 2 development 2020 CONJUGATED Solid IMMUNOSTIMULANT ALT-702 IND and Phase 1 tri
Slide 5: NASH
NASH • NAFLD is present in up to 90% of obese patients LARGELY A DISEASE • Liver fat represents the breakdown of OF OBESITY peripheral fat, not de novo hepatic synthesis AND ECTOPIC BODY FAT • 40% of NASH patients develop NAFLD recurrence one year after liver transplant - i.e., the underlying diseas
Slide 6: NASH
NASH • The treatment of obesity remains the cornerstone of NASH and NAFLD therapy 7-10% BODY WEIGHT LOSS • Meaningful weight loss is rarely achieved REVERSES without medical intervention NASH PROGRESSION • Current drugs have failed to deliver the weight loss achieved by bariatric surgery 6
Slide 7: Dual agonists significantly improve upon GLP-1 agonist-induced weight loss
Dual agonists significantly improve upon GLP-1 agonist- induced weight loss METABOLIC MODULATORS ANTI- (GLP-1 agonists) INFLAMMATORIES Only metabolic modulators are associated with significant weight loss LIVER-SPECIFIC ANTI- EFFECTORS FIBROTICS 77
Slide 8: ALT-801: Optimized for NASH and Weight Loss
ALT-801 GLP-1 GLUCAGON ↓ blood glucose ↑ energy expenditure ↓ appetite ↑ adipose browning OPTIMIZED ↓ inflammation ↑ lipolysis/gluconeogenesis ↑ mobilization of liver fat FOR NASH AND WEIGHT Indirect effects on liver Direct effects on liver LOSS Substantial reductions in: • body weight • liver fat,
Slide 9: ALT-801 Weight Loss
Mouse DIO Model After 4 Weeks of Treatment ALT-801 110 dose titration Vehicle 100 25% Body Weight 90 Semaglutide (12nmol/kg) (% Baseline) WEIGHT 80 ALT-801 (12nmol/kg) LOSS 70 OVER ONE MONTH 0 4 8 12 16 Time (days) 20 24 28 • More than 2x the weight loss of semaglutide • Body weight decreased to lea
Slide 10: ALT-801 Reduction in Liver Fat
Gubra Model After 12 Weeks of Treatment Liver fat ALT-801 VEHICLE SEMAGLUTIDE REDUCTION IN LIVER FAT TO LEAN ELAFIBRANOR ALT-801 NORMAL VEIN 10
Slide 11: ALT-801 Change in NAFLD Activity Score
Gubra Model After 12 Weeks of Treatment ALT-801 Change in NAFLD Activity Score (NAS) 30% 20% Treatment +6% Treatment 10% GREATER 0% -10% onon REDUCTION IN in NAS -20% -18% in NAS -30% FAT-DRIVEN Percent Change -35% -40% -32% % Change -42% LIVER -50% -60% -61%* INFLAMMATION -70% -80% ALT-801 vehicle
Slide 12: ALT-801 Normalization of Plasma ALT
Gubra Model After 12 Weeks of Treatment ALT-801 Change in Plasma Alanine Aminotransferase (IU/L) Plasma alanine aminotransferase (IU/L) 400 300 NORMALIZATION 200 OF **** **** PLASMA ALT 100 **** **** ULN 0 Vehicle ALT-801 elafibranor semaglutide 5nmol/kg 10nmol/kg 78µmol/kg 10nmol/kg **** p < .0001
Slide 13: ALT-801 Reduction in COL1A1
Gubra Model After 12 Weeks of Treatment ALT-801 QUANTITATIVE REDUCTION IN COL1A1 (similar effects with galectin-3) Liver COL1A1 content (mg) 400 ** GREATER EFFECTS ON **** 200 FIBROSIS **** **** 0 Vehicle ALT-801 elafibranor semaglutide 5nmol/kg 10nmol/kg 78µmol/kg 10nmol/kg ** p < .0001, **** p < .
Slide 14: ALT-801 Upcoming Milestones
• IND – 2H 2020 • Anticipated initiation of clinical trials – Q4 2020 • Expected data readout on Phase 1b trial – 1H 2021 Potent effects on • Liver fat content (MRI-PDFF) • Liver inflammation (ALT) • Fibrosis (Pro-C3) • Weight Loss …all key predictors of success in later phase trials 14
Slide 15: HBV: Currently Approved Therapeutics Do Not Lead To A Cure
HBV: Currently Approved Therapeutics Do Not Lead To A Cure Immune activation will be required for significant impact HBV T Cell Function • Current antivirals prevent disease progression but rarely clear infection • Novel direct-acting antivirals alone Liver unlikely to provide functional cure Cells
Slide 16: HepTcell Progress and Next Steps
• Completed successful ex-US Phase 1 study in chronically infected subjects demonstrating T cell activation • File IND in 2020 following successful pre-IND meeting held with FDA in June 2019 • Prepare for Phase 2 program in expanded chronic HBV patient population • Exploit immune activation of HepTc
Slide 17: ALT-702: Conjugated Immunostimulant for Cancer
ALT-702: CONJUGATED IMMUNOSTIMULANT FOR CANCER Potent TLR7/8 agonist for cancer immunotherapy Anchored approach prolongs immune stimulation while avoiding systemic toxicity Platform technology can be applied to other immunostimulants or therapeutics Fully synthetic product - Low COGs IND e
Slide 18: NasoShield: Differentiated Anthrax Vaccine
NasoShield: Differentiated Anthrax Vaccine Significant opportunity to improve protection in a bioterrorism event Competition NasoShield • BioThrax® - Only approved vaccine • Single-dose intranasal vaccine • 3 dose regimen candidate • Requires an adjuvant • No adjuvant required • Subcutaneous injecti
Slide 19: Financial Highlights
FINANCIAL HIGHLIGHTS Altimmune is well positioned to advance multiple product candidates C $42 MILLION $10 MILLION 15.3 MILLION SHARES R&D FOCUSED CASH ON HAND ANNUAL REVENUE OUTSTANDING 27 employees with 19 at June 30, 2019 in each of last 2 years and 10.1 million warrants primarily engaged in from
Slide 20: BIO Investor Forum
BIO Investor Forum 23 October 2019 20